Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Papillomavirus Infections 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Condylomata Acuminata 1Cancer Survivor 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 6Radiotherapy, Intensity-Modulated 5Cisplatin 5Carboplatin 5Papillomavirus Vaccines 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4artesunic acid 3artemisinin 3Paclitaxel 3Human Papillomavirus Recombinant Vaccine nonavalent 3artenimol 2Vaccines, Synthetic 2Taxes 2Radiation 2Imiquimod 2GX-188 vaccine 2Docetaxel 2Albumin-Bound Paclitaxel 2utomilumab 1toripalimab 1polyphenon E 1infigratinib 1fludarabine phosphate 1fludarabine 1epigallocatechin gallate 1aldesleukin 1Viusid 1Vaccines 1VP-102 1Therapies, Investigational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Papillomavirus Infections × Vaccines, Synthetic × Clear all
NCT00411749 2017-04-21

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Merck Sharp & Dohme LLC

Phase 2 Completed
107 enrolled 12 charts

Papillomavirus Infections

NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
620 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡